Montgomery County Executive Marc Elrich joined Maryland Secretary of State Susan Lee, Maryland Commerce Secretary Harry Coker Jr., County Council President Natali Fani-González and other local leaders to celebrate the opening of Bora Biologics’ new drug substance manufacturing facility in Rockville. The Taiwan-based company acquired MacroGenics’ biologics manufacturing operations for $122.5 million and will continue producing products for MacroGenics while expanding contract manufacturing services for other biotechnology and pharmaceutical companies.
Bora Biologics is retaining all 140 employees who previously worked at the facility and plans to create additional jobs while investing further in the Rockville site. The FDA-approved facility supports both clinical and commercial-stage biologics manufacturing, strengthening Montgomery County’s position as a leader in the life sciences industry. The County is home to more than 350 life sciences companies and serves as the anchor of the BioHealth Capital Region, the nation’s third-largest biopharmaceutical cluster.
“We welcome Bora Biologics to Montgomery County, are happy they’ve retained all the employees who used to work for MacroGenics, and are excited about their plans to invest and grow more jobs here,” Elrich said. “Our highly educated and diverse community, and our ongoing investments in workforce development and innovation lead to more jobs here and also ensure the next generation of life-saving therapies can be developed and produced right here in the County.”
Maryland Commerce Secretary Harry Coker Jr. said Bora’s investment reinforces the state’s reputation as a global life sciences hub. “Companies like Bora Pharmaceuticals are what makes Maryland a global leader in the life sciences,” Coker said. “They bring talent, innovation, and a commitment to delivering transformative treatment to patients.” Bora Pharmaceuticals was also recently recognized by Time magazine as one of the World’s Most Impactful Companies 2026.
